IOVA
Iovance Biotherapeutics, Inc.NASDAQHealthcare$3.43-0.58%ClosedMarket Cap: $1.14B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.00
P/S
4.32
EV/EBITDA
-2.83
DCF Value
$4.12
FCF Yield
-29.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.2%
Operating Margin
-153.1%
Net Margin
-148.4%
ROE
-54.5%
ROA
-61.7%
ROIC
-51.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $86.8M | 215.9% | $-73.5M | $-71.9M | $-0.15 | — |
| FY 2025 | $263.5M | 97.2% | $-403.4M | $-391.0M | $-1.09 | — |
| Q3 2025 | $67.5M | 97.9% | $-94.9M | $-91.3M | $-0.25 | — |
| Q2 2025 | $60.0M | 5.5% | $-113.8M | $-111.7M | $-0.33 | — |
| Q1 2025 | $49.3M | -0.8% | $-121.2M | $-116.2M | $-0.36 | — |
| Q4 2024 | $73.7M | 38.2% | $-86.6M | $-78.6M | $-0.26 | — |
| FY 2024 | $164.1M | 24.4% | $-395.3M | $-372.2M | $-1.28 | — |
| Q3 2024 | $58.6M | 32.0% | $-89.1M | $-83.5M | $-0.28 | — |
| Q2 2024 | $31.1M | -0.8% | $-101.9M | $-97.1M | $-0.34 | — |
| Q1 2024 | $715.0K | -915.5% | $-117.7M | $-113.0M | $-0.42 | — |
| Q4 2023 | $482.0K | -805.6% | $-121.3M | $-116.4M | $-0.45 | — |
| FY 2023 | $1.2M | -804.5% | $-460.6M | $-444.0M | $-1.89 | — |